| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $8,887,423 | 13 | 62 |
Sells | $104,699 | 8 | 38 |
| Satter Muneer A | director | 5 | $8.66M | 0 | $0 | $8.66M |
| Choi Jung | director | 1 | $138,270 | 0 | $0 | $138,270 |
| Carson William H. | director | 7 | $93,369 | 0 | $0 | $93,369 |
| Love Douglas | PRESIDENT AND CEO | 0 | $0 | 1 | $14,812 | $-14,812 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | 0 | $0 | 1 | $16,342 | $-16,342 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | 0 | $0 | 1 | $16,380 | $-16,380 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 0 | $0 | 3 | $26,010 | $-26,010 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 0 | $0 | 3 | $28,387 | $-28,387 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 0 | $0 | 3 | $32,494 | $-32,494 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Over the last 12 months, insiders at Annexon, Inc. have bought $8.89M and sold $104,699 worth of Annexon, Inc. stock.
On average, over the past 5 years, insiders at Annexon, Inc. have bought $7.21M and sold $683,242 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Satter Muneer A (director) — $8.66M. Choi Jung (director) — $138,270. Carson William H. (director) — $93,369.
The last purchase of 4,115 shares for transaction amount of $20,657 was made by Carson William H. (director) on 2025‑12‑30.
| 2025-12-30 | Carson William H. | director | 4,115 0.0034% | $5.02 | $20,657 | +17.86% | ||
| 2025-12-01 | Carson William H. | director | 4,115 0.0037% | $4.47 | $18,394 | +28.93% | ||
| 2025-12-01 | Choi Jung | director | 33,000 0.028% | $4.19 | $138,270 | +28.93% | ||
| 2025-11-21 | Satter Muneer A | director | 422,613 0.3542% | $4.28 | $1.81M | +21.43% | ||
| 2025-11-20 | Satter Muneer A | director | 400,000 0.3509% | $4.48 | $1.79M | +21.31% | ||
| 2025-11-19 | Satter Muneer A | director | 500,000 0.4057% | $3.94 | $1.97M | +27.46% | ||
| 2025-11-18 | Satter Muneer A | director | 500,000 0.4155% | $3.18 | $1.59M | +61.56% | ||
| 2025-11-17 | Satter Muneer A | director | 500,000 0.4139% | $2.99 | $1.5M | +70.20% | ||
| 2025-10-30 | Carson William H. | director | 4,115 0.0039% | $3.17 | $13,045 | +70.99% | ||
| 2025-09-30 | Carson William H. | director | 4,115 0.0037% | $3.05 | $12,551 | +52.46% | ||
| 2025-09-02 | Carson William H. | director | 4,115 0.0038% | $2.09 | $8,600 | +97.83% | ||
| 2025-07-30 | Carson William H. | director | 4,115 0.0035% | $2.43 | $9,999 | +22.39% | ||
| 2025-07-14 | Sale | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 853 0.0008% | $2.61 | $2,226 | +19.92% | |
| 2025-07-14 | Sale | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 1,117 0.001% | $2.58 | $2,882 | +19.92% | |
| 2025-07-14 | Sale | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 1,116 0.001% | $2.58 | $2,879 | +19.92% | |
| 2025-06-30 | Carson William H. | director | 4,115 0.0038% | $2.46 | $10,123 | +28.13% | ||
| 2025-02-18 | Sale | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 6,618 0.006% | $2.95 | $19,523 | -3.33% | |
| 2025-02-18 | Sale | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | 5,515 0.005% | $2.97 | $16,380 | -3.33% | |
| 2025-02-18 | Sale | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 6,912 0.0062% | $2.92 | $20,183 | -3.33% | |
| 2025-02-18 | Sale | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 8,345 0.0074% | $2.91 | $24,284 | -3.33% |
| Satter Muneer A | director | 9728637 8.1346% | $47.57M | 8 | 0 | +2.91% |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 130689 0.1093% | $639,069.21 | 0 | 9 | |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 121616 0.1017% | $594,702.24 | 1 | 12 | +33.07% |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 105084 0.0879% | $513,860.76 | 0 | 16 | |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | 83814 0.0701% | $409,850.46 | 0 | 1 | |
| Carson William H. | director | 54405 0.0455% | $266,040.45 | 15 | 0 | <0.0001% |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | 33479 0.028% | $163,712.31 | 0 | 1 | |
| Choi Jung | director | 33000 0.0276% | $161,370.00 | 1 | 0 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5701926 4.7677% | $27.88M | 2 | 0 | +48.68% |
| Clarus Lifesciences III, L.P. | 10 percent owner | 2730635 2.2832% | $13.35M | 1 | 0 | +33.07% |
| Flynn James E | 10 percent owner | 808914 0.6764% | $3.96M | 1 | 0 | +33.07% |
| Love Douglas | PRESIDENT AND CEO | 351554 0.294% | $1.72M | 1 | 10 | +135.71% |
| Keswani Sanjay | EVP & Chief Medical Officer | 0 0% | $0 | 0 | 1 |
$3,611,891 | 113 | 13.40% | $578.31M | |
$860,541,348 | 82 | -5.10% | $518.06M | |
$63,049,419 | 31 | 2.87% | $534.69M | |
$24,857,912 | 21 | -35.40% | $673.39M | |
$3,556,951 | 18 | 9.64% | $530.03M | |
$46,858,891 | 18 | -11.58% | $573.63M | |
Annexon, Inc. (ANNX) | $59,102,045 | 17 | 8.52% | $584.82M |
$7,254,955 | 14 | 20.70% | $622.95M | |
$92,357,691 | 12 | 87.24% | $672.13M | |
$19,167,169 | 10 | 28.48% | $575.2M | |
$75,069,528 | 10 | 19.77% | $557.19M | |
$140,543,039 | 10 | 0.77% | $599.66M | |
$11,541,901 | 10 | 8.07% | $723.12M | |
$38,624,786 | 9 | 1.26% | $684.69M | |
$49,165,200 | 7 | 12.92% | $658.1M | |
$94,000,000 | 7 | -20.84% | $595.69M | |
$1,746,565 | 4 | -29.05% | $528.02M | |
$7,234,370 | 3 | -3.34% | $604.62M | |
$300,016 | 1 | -50.33% | $548.94M |
| Increased Positions | 85 | +63.91% | 18M | +18.13% |
| Decreased Positions | 54 | -40.6% | 15M | -15.06% |
| New Positions | 31 | New | 7M | New |
| Sold Out Positions | 21 | Sold Out | 9M | Sold Out |
| Total Postitions | 164 | +23.31% | 103M | +3.07% |
| Fmr Llc | $51,971.00 | 7.64% | 11.08M | -5M | -29.4% | 2025-09-30 |
| Blackrock, Inc. | $37,046.00 | 5.45% | 7.9M | -63,360 | -0.8% | 2025-09-30 |
| Bvf Inc/Il | $32,830.00 | 4.83% | 7M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $29,550.00 | 4.35% | 6.3M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $27,367.00 | 4.02% | 5.84M | +469,073 | +8.74% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $24,618.00 | 3.62% | 5.25M | 0 | 0% | 2025-09-30 |
| Bellevue Group Ag | $24,188.00 | 3.56% | 5.16M | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $14,210.00 | 2.09% | 3.03M | +2M | +263.93% | 2025-09-30 |
| Millennium Management Llc | $13,239.00 | 1.95% | 2.82M | +308,689 | +12.28% | 2025-09-30 |
| Woodline Partners Lp | $12,374.00 | 1.82% | 2.64M | +2M | +150.38% | 2025-09-30 |